BTAI
BioXcel Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.07
+63.86%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
-96.1%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Aug 14, 2026 | Atkins Susan E. · director | A-Award | 17,000 | $1.06 |
| Jun 17, 2026 | Steinhart Richard I · officer: Chief Financial Officer | M-Exempt | 35 | $0.00 |
| Jun 17, 2026 | Yocca Frank · officer: Chief Scientific Officer | M-Exempt | 35 | $0.00 |
| Jun 17, 2026 | Mehta Vimal · director, officer: CEO and President | M-Exempt | 219 | $0.00 |
| Jun 17, 2026 | Rodriguez Javier · officer: See Remarks | M-Exempt | 35 | $0.00 |
| May 22, 2026 | Mehta Vimal · director, officer: CEO and President | M-Exempt | 49,758 | $0.00 |
| May 22, 2026 | Mehta Vimal · director, officer: CEO and President | Sale | 19,419 | $1.09 |
| May 22, 2026 | Rodriguez Javier · officer: See Remarks | M-Exempt | 17,500 | $0.00 |
| May 22, 2026 | Yocca Frank · officer: Chief Scientific Officer | Sale | 6,845 | $1.08 |
| May 22, 2026 | Yocca Frank · officer: Chief Scientific Officer | M-Exempt | 17,500 | $0.00 |
| May 22, 2026 | Rodriguez Javier · officer: See Remarks | Sale | 6,560 | $1.08 |
| May 22, 2026 | Steinhart Richard I · officer: Chief Financial Officer | M-Exempt | 17,500 | $0.00 |
| May 22, 2026 | Steinhart Richard I · officer: Chief Financial Officer | Sale | 6,845 | $1.08 |
| May 7, 2026 | Yocca Frank · officer: Chief Scientific Officer | M-Exempt | 9,000 | $0.00 |
| May 7, 2026 | Mehta Vimal · director, officer: CEO and President | M-Exempt | 18,000 | $0.00 |
| May 7, 2026 | Steinhart Richard I · officer: Chief Financial Officer | M-Exempt | 9,000 | $0.00 |
| May 7, 2026 | Rodriguez Javier · officer: See Remarks | M-Exempt | 9,000 | $0.00 |
| Mar 16, 2026 | Steinhart Richard I · officer: Chief Financial Officer | M-Exempt | 35 | $0.00 |
| Mar 16, 2026 | Yocca Frank · officer: Chief Scientific Officer | M-Exempt | 35 | $0.00 |
| Mar 16, 2026 | Yocca Frank · officer: Chief Scientific Officer | M-Exempt | 33 | $0.00 |
| Mar 16, 2026 | Rodriguez Javier · officer: See Remarks | M-Exempt | 35 | $0.00 |
| Mar 16, 2026 | Rodriguez Javier · officer: See Remarks | M-Exempt | 33 | $0.00 |
| Mar 16, 2026 | Mehta Vimal · director, officer: CEO and President | M-Exempt | 164 | $0.00 |
| Mar 16, 2026 | Mehta Vimal · director, officer: CEO and President | M-Exempt | 219 | $0.00 |
| Mar 16, 2026 | Steinhart Richard I · officer: Chief Financial Officer | M-Exempt | 33 | $0.00 |
| Jan 12, 2026 | Laumas Sandeep · director | A-Award | 17,000 | $2.01 |
| Jan 12, 2026 | Patni Rajiv · director | A-Award | 17,000 | $2.01 |
| Jan 12, 2026 | MUELLER PETER · director | A-Award | 17,000 | $2.01 |
| Jan 12, 2026 | MACK DAVID J. · director | A-Award | 17,000 | $2.01 |
| Jan 12, 2026 | Bray June · director | A-Award | 17,000 | $2.01 |
Institutional positioning
13F filings over the trailing two quarters
New 18Increased 21Reduced 16Sold out 3
| Filer | Action | Shares | Filed |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLC | Increased | 2,114,710 | Aug 14, 2026 |
| MILLENNIUM MANAGEMENT LLC | Increased | 1,936,760 | May 15, 2026 |
| ARMISTICE CAPITAL, LLC | New Position | 1,910,076 | May 15, 2026 |
| OAKTREE CAPITAL MANAGEMENT LP | Increased | 1,380,248 | Aug 14, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 919,545 | Aug 13, 2026 |
| Oaktree Fund Advisors, LLC | Increased | 245,585 | Aug 14, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Increased | 242,251 | Aug 12, 2026 |
| OAKTREE CAPITAL MANAGEMENT LP | Unchanged | 241,188 | May 20, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Increased | 230,168 | May 15, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 207,339 | May 15, 2026 |
| BlackRock, Inc. | Increased | 179,433 | Aug 7, 2026 |
| UBS Group AG | Increased | 158,065 | Aug 13, 2026 |
| CITADEL ADVISORS LLC | New Position | 149,220 | Sep 2, 2026 |
| VANGUARD FIDUCIARY TRUST CO | Increased | 136,937 | Aug 13, 2026 |
| JONES FINANCIAL COMPANIES LLLP | Reduced | 131,789 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Aug 14, 2026